Literature DB >> 31896950

Multiplicity and the marginal benefits of bevacizumab in malignant solid tumours.

Nathan D Gay1, Derrick Tao1, Vinay Prasad2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31896950      PMCID： PMC6927779          DOI： 10.3747/co.26.4845

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  5 in total

Review 1.  Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.

Authors:  Vishal Ranpura; Sanjaykumar Hapani; Shenhong Wu
Journal:  JAMA       Date:  2011-02-02       Impact factor: 56.272

2.  Drug Development at the Portfolio Level Is Important for Policy, Care Decisions and Human Protections.

Authors:  Jonathan Kimmelman; Benjamin Carlisle; Mithat Gönen
Journal:  JAMA       Date:  2017-09-19       Impact factor: 56.272

Review 3.  The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials.

Authors:  Giandomenico Roviello; Thomas Bachelot; Clifford A Hudis; Giuseppe Curigliano; Andrew R Reynolds; Roberto Petrioli; Daniele Generali
Journal:  Eur J Cancer       Date:  2017-02-24       Impact factor: 9.162

4.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 5.  The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review.

Authors:  Limor Amit; Irit Ben-Aharon; Liat Vidal; Leonard Leibovici; Salomon Stemmer
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.